Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 328

1.

Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention.

Andreoni M, Mussi C, Bellagamba R, Di Campli F, Montinaro V, Babiloni C.

New Microbiol. 2017 Oct 10;40(4). [Epub ahead of print]

2.

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.

Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F.

J Antimicrob Chemother. 2017 Sep 18. doi: 10.1093/jac/dkx302. [Epub ahead of print]

PMID:
28961921
3.

Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

Santoro MM, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G.

Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197. [Epub ahead of print]

PMID:
28935850
4.

Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success?

Svicher V, Marchetti G, Ammassari A, Ceccherini-Silberstein F, Sarmati L; Impact Study Group.

AIDS Rev. 2017 Sep 19;19(3). [Epub ahead of print]

PMID:
28926559
5.

Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Parisi SG, Andreis S, Basso M, Cavinato S, Scaggiante R, Franzetti M, Andreoni M, Palù G, Cattelan AM.

Med Microbiol Immunol. 2017 Sep 1. doi: 10.1007/s00430-017-0518-x. [Epub ahead of print]

PMID:
28864951
6.

Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.

Parisi SG, Basso M, Mengoli C, Scaggiante R, Andreis S, Franzetti MM, Cattelan AM, Zago D, Cruciani M, Andreoni M, Piovesan S, Palù G, Alberti A.

Ann Gastroenterol. 2017;30(5):534-541. doi: 10.20524/aog.2017.0175. Epub 2017 Jul 4.

7.

NK cells of HIV-1-infected patients with poor CD4+ T-cell reconstitution despite suppressive HAART show reduced IFN-γ production and high frequency of autoreactive CD56bright cells.

Giuliani E, Vassena L, Di Cesare S, Malagnino V, Desimio MG, Andreoni M, Barnaba V, Doria M.

Immunol Lett. 2017 Oct;190:185-193. doi: 10.1016/j.imlet.2017.08.014. Epub 2017 Aug 19.

PMID:
28826739
8.

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.

Andreis S, Basso M, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, Rossi MC, Francavilla E, Boldrin C, Alvarez M, Dal Bello F, Mengoli C, Turriziani O, Sarmati L, Antonelli G, Andreoni M, Palù G, Parisi SG.

J Glob Antimicrob Resist. 2017 Sep;10:106-112. doi: 10.1016/j.jgar.2017.05.011. Epub 2017 Jul 18.

PMID:
28732792
9.

Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.

Fabeni L, Berno G, Fokam J, Bertoli A, Alteri C, Gori C, Forbici F, Takou D, Vergori A, Zaccarelli M, Maffongelli G, Borghi V, Latini A, Pennica A, Mastroianni CM, Montella F, Mussini C, Andreoni M, Antinori A, Perno CF, Santoro MM; Resistance Study Group.

J Clin Microbiol. 2017 Sep;55(9):2827-2837. doi: 10.1128/JCM.00656-17. Epub 2017 Jul 12.

PMID:
28701420
10.

Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.

Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G.

Clin Microbiol Infect. 2017 Jun 29. pii: S1198-743X(17)30347-6. doi: 10.1016/j.cmi.2017.06.023. [Epub ahead of print]

PMID:
28668466
11.

Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review.

Gentile G, Andreoni M, Antonelli G, Sarmati L.

Clin Microbiol Infect. 2017 Jun 28. pii: S1198-743X(17)30348-8. doi: 10.1016/j.cmi.2017.06.024. [Epub ahead of print] Review.

PMID:
28668465
12.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2017 May 18;12(5):e0177352. doi: 10.1371/journal.pone.0177352. eCollection 2017.

13.

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.

d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A, Puoti M; Icona Foundation and HepaIcona Study Group.

PLoS One. 2017 May 17;12(5):e0177402. doi: 10.1371/journal.pone.0177402. eCollection 2017.

14.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2017 Apr;40(2):86-98.

15.

Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome?

Moscato GMF, Giacobbi E, Anemona L, Di Cesare S, Di Matteo G, Andreoni M, Mauriello A, Moschese V.

Front Pediatr. 2017 May 2;5:95. doi: 10.3389/fped.2017.00095. eCollection 2017.

16.

Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients.

Ricciardi A, Gentilotti E, Coppola L, Maffongelli G, Cerva C, Malagnino V, Mari A, Di Veroli A, Berrilli F, Apice F, Toschi N, Di Cave D, Parisi SG, Andreoni M, Sarmati L.

PLoS One. 2017 May 15;12(5):e0176881. doi: 10.1371/journal.pone.0176881. eCollection 2017.

17.

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

PMID:
28497758
18.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
19.

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel.

Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party.

Dig Liver Dis. 2017 Jul;49(7):731-741. doi: 10.1016/j.dld.2017.03.027. Epub 2017 Apr 12.

PMID:
28456519
20.

Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.

Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group.

Clin Microbiol Infect. 2017 Oct;23(10):777.e1-777.e4. doi: 10.1016/j.cmi.2017.04.005. Epub 2017 Apr 12.

PMID:
28412381

Supplemental Content

Loading ...
Support Center